跳至主要内容
临床试验/NCT05634044
NCT05634044已完成不适用

eNose Validation Study: Correlating Volatile Organic Compounds With Daily Fiber Intake

Rush University Medical Center2 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2022年11月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
22
试验地点
2
主要终点
Accuracy of this device to detect increased intake of fiber

研究概览

简要总结

Monitoring dietary intake and digestion is important for both medical monitoring and assessing the wellness of individuals. Fiber is an important nutrient that is not focused on enough, despite it being an essential nutrient for the bacteria and other micro-organisms that reside in our GI Tracts, known as the microbiome. Ingestion of fermentable soluble and insoluble dietary fiber has been shown to result in the production of short-chain fatty acids (SCFA) by the colonic microbiome. These SCFAs are volatile organic compounds (VOCs) and can be detected in the atmosphere of a bowel movement. We have developed an e-Nose device that once placed in the bathroom records volatile organic compounds (VOCs) from the ambient air. We have demonstrated in an "N of 1" study a strong correlation between the eNose output and grams of daily fiber intake.

The current study is being proposed to validate the e-Nose device on a larger population. This is a nonmedical device that is not regulated by the FDA. A total of 40 subjects are invited to participate in this 3-week study. Participants will be asked to complete questionnaires and provide stool and blood samples. The subjects will place the eNose device in their bathroom and record their daily food intake over a 3-week period.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females, age 21-65, with no chronic medical diseases (mild and controlled hypertension, and controlled hyperlipidemia are acceptable).
  • Willingness to eat 2 prebiotic bar per day for two weeks and collect stool samples three times, provide blood samples twice and complete questionnaires.

排除标准

  • Patients on a restricted diet (e.g., gluten-free diet, Paleo diet, vegetarian or vegan diet)
  • Allergy to almonds, flax seed, or coconuts
  • Chronic GI disorders (Inflammatory bowel disease, Irritable Bowel Syndrome on regular therapy taking fiber or MiraLAX is acceptable to be enrolled; celiac disease, colon cancer, intestinal resection,)
  • Chronic NSAID use (more than 3 days per week)
  • Antibiotic use in the last 12 weeks
  • BMI > 35 or < 18
  • Inability to sign an informed consent form
  • Non-English speaker

结局指标

主要结局

Accuracy of this device to detect increased intake of fiber

时间窗: 3 weeks

Assessed by comparing percentage change in volatile organic compounds (measured in OHMS) against the daily fiber intake in grams

次要结局

  • Tolerability of prebiotic bar(3 weeks)
  • Ability of eNose to detect increased production of SCFA- positive correlation between enose signals and each of three SCFA and total SCFA levels in stool(3 weeks)
  • Impact of fiber bar in microbiota composition(3 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Robin Voigt

Principle Investigator

Rush University Medical Center

研究点 (2)

Loading locations...

相似试验